PL1912673T3 - Sposób przyłączania cząsteczek efektorowych do białek - Google Patents
Sposób przyłączania cząsteczek efektorowych do białekInfo
- Publication number
- PL1912673T3 PL1912673T3 PL06744294T PL06744294T PL1912673T3 PL 1912673 T3 PL1912673 T3 PL 1912673T3 PL 06744294 T PL06744294 T PL 06744294T PL 06744294 T PL06744294 T PL 06744294T PL 1912673 T3 PL1912673 T3 PL 1912673T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- effector molecules
- proteins
- attaching
- cysteines
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000012636 effector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 4
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 150000001945 cysteines Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Catalysts (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0513852.4A GB0513852D0 (en) | 2005-07-06 | 2005-07-06 | Biological products |
| EP06744294A EP1912673B1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
| PCT/GB2006/002416 WO2007003898A1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1912673T3 true PL1912673T3 (pl) | 2011-07-29 |
Family
ID=34856761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06744294T PL1912673T3 (pl) | 2005-07-06 | 2006-06-29 | Sposób przyłączania cząsteczek efektorowych do białek |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8378073B2 (pl) |
| EP (1) | EP1912673B1 (pl) |
| JP (1) | JP5203188B2 (pl) |
| CN (1) | CN101212984B (pl) |
| AT (1) | ATE502650T1 (pl) |
| AU (1) | AU2006264684B2 (pl) |
| CA (1) | CA2613481C (pl) |
| DE (1) | DE602006020878D1 (pl) |
| DK (1) | DK1912673T3 (pl) |
| ES (1) | ES2361096T3 (pl) |
| GB (1) | GB0513852D0 (pl) |
| PL (1) | PL1912673T3 (pl) |
| PT (1) | PT1912673E (pl) |
| SI (1) | SI1912673T1 (pl) |
| WO (1) | WO2007003898A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| WO2013004844A1 (en) | 2011-07-07 | 2013-01-10 | Novo Nordisk A/S | Drug delivery injection pen with add-on dose capturing and display module |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| EP3079722B1 (en) * | 2013-12-13 | 2021-03-24 | Novo Nordisk Health Care AG | Method for thioether conjugation of proteins |
| MX2016010295A (es) * | 2014-02-11 | 2016-10-17 | Seattle Genetics Inc | Reduccion selectiva de proteinas. |
| GB201419184D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| ES3046837T3 (en) | 2014-12-22 | 2025-12-02 | UCB Biopharma SRL | Method of protein manufacture |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016196017A1 (en) | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2019009372A (es) * | 2017-02-08 | 2019-12-11 | Pfizer | Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas. |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| WO2019183671A1 (en) * | 2018-03-28 | 2019-10-03 | Proteomics International Pty Ltd | Methods for measuring relative oxidation levels of a protein |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| BR112023008265A2 (pt) | 2020-12-07 | 2024-02-06 | UCB Biopharma SRL | Anticorpos contra interleucina-22 |
| AR125732A1 (es) | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | Anticuerpos anti-trem1 |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728430A (en) * | 1986-02-10 | 1988-03-01 | Millipore Corporation | Diafiltration method |
| US5216183A (en) * | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
| US5225194A (en) * | 1989-11-13 | 1993-07-06 | Ldc Research Corporation | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases |
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| US20040121415A1 (en) * | 1996-12-10 | 2004-06-24 | King David John | Monovalent antibody fragments |
| GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6423231B1 (en) * | 1998-10-30 | 2002-07-23 | Nephros, Inc. | Non-isosmotic diafiltration system |
| US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| US6406631B1 (en) * | 1999-07-30 | 2002-06-18 | Nephros, Inc. | Two stage diafiltration method and apparatus |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| CN1621091A (zh) * | 2003-11-28 | 2005-06-01 | 付经国 | 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法 |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| US7908694B1 (en) * | 2008-09-24 | 2011-03-22 | Robert Sloane | Mattress cover apparatus with integrated seals |
-
2005
- 2005-07-06 GB GBGB0513852.4A patent/GB0513852D0/en not_active Ceased
-
2006
- 2006-06-29 CA CA2613481A patent/CA2613481C/en not_active Expired - Lifetime
- 2006-06-29 PL PL06744294T patent/PL1912673T3/pl unknown
- 2006-06-29 AT AT06744294T patent/ATE502650T1/de active
- 2006-06-29 SI SI200631002T patent/SI1912673T1/sl unknown
- 2006-06-29 DE DE602006020878T patent/DE602006020878D1/de not_active Expired - Lifetime
- 2006-06-29 ES ES06744294T patent/ES2361096T3/es not_active Expired - Lifetime
- 2006-06-29 DK DK06744294.7T patent/DK1912673T3/da active
- 2006-06-29 WO PCT/GB2006/002416 patent/WO2007003898A1/en not_active Ceased
- 2006-06-29 PT PT06744294T patent/PT1912673E/pt unknown
- 2006-06-29 AU AU2006264684A patent/AU2006264684B2/en not_active Expired
- 2006-06-29 CN CN2006800234116A patent/CN101212984B/zh not_active Expired - Lifetime
- 2006-06-29 JP JP2008518969A patent/JP5203188B2/ja not_active Expired - Lifetime
- 2006-06-29 US US11/994,053 patent/US8378073B2/en active Active
- 2006-06-29 EP EP06744294A patent/EP1912673B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006264684B2 (en) | 2011-11-03 |
| GB0513852D0 (en) | 2005-08-10 |
| US8378073B2 (en) | 2013-02-19 |
| EP1912673A1 (en) | 2008-04-23 |
| CN101212984A (zh) | 2008-07-02 |
| EP1912673B1 (en) | 2011-03-23 |
| DE602006020878D1 (de) | 2011-05-05 |
| WO2007003898A8 (en) | 2008-10-09 |
| JP2008544976A (ja) | 2008-12-11 |
| ES2361096T3 (es) | 2011-06-13 |
| SI1912673T1 (sl) | 2011-10-28 |
| WO2007003898A1 (en) | 2007-01-11 |
| CA2613481C (en) | 2014-11-25 |
| JP5203188B2 (ja) | 2013-06-05 |
| PT1912673E (pt) | 2011-04-14 |
| CA2613481A1 (en) | 2007-01-11 |
| DK1912673T3 (da) | 2011-05-02 |
| ATE502650T1 (de) | 2011-04-15 |
| AU2006264684A1 (en) | 2007-01-11 |
| US20080306246A1 (en) | 2008-12-11 |
| CN101212984B (zh) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1912673T1 (sl) | Postopek za povezovanje efektor molekul na proteine | |
| IL190333A (en) | Process and intermediates for the synthesis of caspofungin | |
| MY160468A (en) | Novel amino azaheterocyclic carboxamides | |
| NZ597769A (en) | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli | |
| CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
| ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
| MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
| EA201070510A1 (ru) | Система, образованная пневматической шиной и гибким органом | |
| ATE517917T1 (de) | Herstellung eines rekombinanten il-18-bindenden proteins | |
| MY151017A (en) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | |
| TW200716525A (en) | Process for preparation of sulfamide derivatives | |
| ATE496036T1 (de) | Zwischenprodukte für die herstellung von pramipexol | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| GB0508318D0 (en) | Organic compounds | |
| TW200740769A (en) | Novel process | |
| ATE517900T1 (de) | Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung | |
| WO2006079057A3 (en) | Methods and compositions for specific inhibition of protein splicing by small molecules | |
| TW200633977A (en) | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives | |
| TW200716564A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| ATE461934T1 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren | |
| EA200701852A1 (ru) | Производные аминокислот | |
| ATE496941T1 (de) | Herstellung von insulinkonjugaten | |
| PT1819704E (pt) | Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase | |
| MX2007013872A (es) | Procedimiento para la produccion de 4-bifenililazetidina-2-onas. | |
| TW200716555A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |